• Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

Merck Pharmaceuticals Analysis. Merck is a healthy company to invest in with a diverse portfolio since their merger with Schering-Plough in 2007. Before investing however, there are a few things to consider.

Extracts from this document...


Merck: Leading the World in Pharmaceutical and Chemical Production Amber Stone MGT 531 December 1, 2011 Leslie Ann L. Dunn, MBA, JD Merck: Leading the World in Pharmaceutical and Chemical Production Even though Merck faces threats from generic competition, they are the world's leader in healthcare and chemical production because their pioneering inventions save lives which drives continued sales growth. As a mutual fund manager, big pharma means big business. After all, there's no doubt that medicine saves lives. Both innovative and lucrative, Chief Research Officers agree that risky pharmaceutical investments can lead to great returns. Merck is a healthy company to invest in with a diverse portfolio since their merger with Schering-Plough in 2007. Before investing however, there are a few things to consider. Strengths Weaknesses * Increased late stage R&D pipeline * Consistent output of blockbuster products * Gardasil and Zostavax patent extension * Balance of high and low risk products * Expansion of innovative biotechnology and pharmacogenomics * Market expansion through acquisitions * Output of drugs that target niche diseases (Opposite of blockbusters) * Patent expiration dates become public property * Generic competition as patients opt for less expensive treatments * ENHANCE trial effecting spending trends of blockbuster Vytorin and Zeta Opportunities Threats * Merger with Schering-Plough in November 2009 puts them on track to be the second largest big pharma * Schering-Plough's recent merger with Organon Biosciences broadening women's health and animal health portfolios * Acquisition within the immunology & inflammation portfolio adding $2+ billion annual sales * Population continually aging causing increased product demand * Patients increasingly have access to unbiased drug information and current litigation which may lead them to switch prescriptions * Unexpected success of the Wyeth and Pfizer merger through cost cutting * Billions at stake from J&J litigation * Regulatory failure of products in late stage pipeline Upon aligning forces with its Zetia/Vytoria marketing partner who had recently acquired Organon Biosciences, Merck vastly improved their late-pipeline and increased their market share of women's health and animal health products. ...read more.


MPMB also states that Anti-TNF drugs are expensive not only expensive but have adverse side effects. The drugs are also not effective in chronic disease treatment (MPKB 1). When Pfizer merged with Wyeth, together they formed a pharmacaceutical company that had yet to be seen. In 2008 the companies' total sales tipped the scale at over $70 billion. Their prescription sales were $10 billion shy of their total around $60 billion (PharmaWatch 32). In evaluating the Pfizer-Wyeth merger, according to Pharma Watch, one must take into consideration that in order for it to be profitable, they must cut cost aggressively. To find the revenue loss resolution, they must consider all options for overhead reduction (34). In conclusion, although Merck faces significant financial risk upon patent expiration of their highest selling products, they remain a world leader in healthcare and chemical production for two main reasons. First, Merck has continued sales growth. But most importantly, Merck saves lives with their innovative inventions. As mutual fund manager, based on the information gained from this analysis the strongest aspects of the SWOT analysis that influence my decision to invest in this company are its increased late stage R&D pipeline, consistent record of successful blockbuster products and recent portfolio expansion with the Schering-Plough merger. PART II Merck's overall financial health shows positive future revenue growth potential. According to Merck's income statement and by my calculations, there was a 32% profit increase in 2009 alone. This means that Merck earned an additional 8,926,000 annually on top of their 2008 earnings. In 2010 Merck increased their earnings by 40% gaining an impressive 18,559,000 annually on their already remarkable 2009 profits. Overall, between 2009 and 2010 post Schering Merger, the company has managed to increase their take home by almost 300%. With these calculations, I gather that Merck is in terrific financial health ("Merck Annual Report" 2011). Merck's Income Statement reflects continued revenue growth potential. ...read more.


Currently Merck has a wide variety of products with no specific focus. The idea behind Pfizer's plan is to concentrate on all the major diseases that are effecting the population which will increase the demand for the drugs or therapy. In other words, by marketing products for major illnesses they are able to maximize full blockbuster drug potential. Also, Pfizer is breaking pharmaceutical ground by expanding into China. By forming a partnership with Japanese pharmaceutical firm Takeda they are able to promote the Type 2 Diabetes Actos (part of their "Invest to Win" strategy) across China (13). From a global perspective Merck can look to Pfizer's innovative strategy to develop treatments for cancer types that are common in East Asia (14). References Abbott Financial Statement. (2011). Retrieved from http://finance.yahoo.com/q/is?s=ABT+Income+Statement&annua Amst,Catherine, Amy Barrett, Michael Arndt, and John Carey. 2004. "THE WANING OF THE BLOCKBUSTER." Businessweek no. 3904: 36-38. Business Source Complete, EBSCOhost (accessed November 23, 2011). Anti-TIF. (2010). Retrieved from http://mpkb.org/home/othertreatments/antitnf Big Pharma's Comeback. (2010). Retrieved from http://www.forbes.com/sites/matthewherper/2010/11/15/big-pharmas-comeback/ Big Pharma's 2009-2013 Patent Cliff. (2010). Retrieved from http://aladinrc.wrlc.org/bitstream/1961/9359/1/Jardines,%20Ben%20-%20Spring%20'10%20(P).pdf BMY Annual Income Statement. (2011). Retrieved from http://finance.yahoo.com/q/is?s=BMY+Income+Statement&annual Collins, T. P. (2010). Is Gardasil Good Medicine?. National Catholic Bioethics Quarterly, 10(3), 459-469. DATAMONITOR: MarketWatch: Pharmaceuticals. Retrieved from http://www.farmavita.net/content/view/1059/51/ on November 23, 2011. DATAMONITOR: Merck KGaA. (2010). Merck KGaA SWOT Analysis, 1-8. References DATAMONITOR: Schering-Plough Corporation. (2009). Schering-Plough Corporation SWOT Analysis, 1-10. Granier, L., & Trinquard, S. (2010). Entry Deterrence and Mergers under Price Competition in Pharmaceutical Markets. Applied Economics, 42(1-3), 297-309. Herper, M. (2011). The Blockbuster Drug Comes to an End. Forbes, 187(7), 26. J&J acquires Merck's stake in joint venture. (2011). Retrieved from http://finance.yahoo.com/news/JJ-acquires-Mercks-stake-in-apf-2857310221.html?x=0 Kesit, D. (2009). Strategic Analysis of the World Pharmaceutical Industry. Management, 14(1), 59-76. Laustsen, G., & Neilson, T. (2007). Drug news. Prevent shingles with Zostavax. Nurse Practitioner, 32(6), 6-7. Merck and Patent Monopolies. (2007). Retrieved from http://helvidiuspachyderm.wordpress.com/2007/02/19/merck-and-patent-monopolies/ Merck Annual Report. (2011). Retrieved from http://www.merck.com/investors/financials/annual-reports/ar_2010.html Merck Deploys Web-Based Visualization and Data Analysis Solution Enhancing Drug Discovery Efforts. (2011). Retrieved from http://spotfire.tibco.com/~/media/Files/Collateral/Case-Studies/Merck. ...read more.

The above preview is unformatted text

This student written piece of work is one of many that can be found in our University Degree Finance section.

Found what you're looking for?

  • Start learning 29% faster today
  • 150,000+ documents available
  • Just £6.99 a month

Not the one? Search for your essay title...
  • Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

See related essaysSee related essays

Related University Degree Finance essays

  1. Financial analysis of Wipro ltd. The ratio analysis of the company has been derived ...

    Year 2003-04 2004-05 2005-06 2006-07 2007-08 Trend 16.3 19.4 19.2 19.8 17.7 Table 5.6 Net Profit Ratio Analysis Figure 5.6 Net Profit Ratio Analysis Interpretation * After observing the figure the ratio is fluctuating. * Company has rise in its net profit in 2006-07 as compared to the previous year because the company has increased its sales 41.45% .

  2. Merchant Banking-100 marks project

    He shall not keep any open position in respect of allocation of sales or purchases affected in a day. Such transactions shall be at the prevailing market price. He shall segregate each client's funds and portfolio of securities and keep them separately from his own funds and securities and be responsible for safe keeping of clients funds and securities.

  1. Project on portfolio management in Mutual Funds. The analysis and advice presented in ...

    Their portfolio mirrors the benchmark index both in terms of composition and individual stock weightages. ii) Equity diversified funds- 100% of the capital is invested in equities spreading across different sectors and stocks. iii|) Dividend yield funds- it is similar to the equity diversified funds except that they invest in companies offering high dividend yields.

  2. IPO Pricing for Boston Beer Company Inc.

    Ale Brewery Boston Beer Company P/E Ratio on 11/20/95 100 36 49.81 Average compound annual growth rate of volume sales from 90-94 (see appendix 2 for calculations) 111% 41% 56% P/E/G Ratio 11/20/95 0.9 0.88 0.89 Value of Earnings, year end 1995 $6,269,333 Value of Equity, year end 1995 $312,279,199

  1. HDFC Life InsuranceCompany Limited

    Sovereign 0.01% 7.27% GOI 03/09/2013 Sovereign 0.33% 7.49% GOI Mat. 16 Apr 2017 Sovereign 0.58% 7.59% GOI MAT 12/04/2016 Sovereign 2.58% 7.99% GOI MD 09-JULY-2017 Sovereign 0.62% 8.07% GOI 15/01/2017 Sovereign 0.32% 8.20% GOI 15/02/2022 Sovereign 2.80% 8.24% GOI 2018 Mat 22/04/2018 Sovereign 0.00% 8.33% GOI 2036 MD 070636 Sovereign

  2. Hampton Machine Tool Company

    Furthermore, the company would be more apt to face deviations from forecasted sales (esp. lower actual sales) under alternative E than in alternative D. Under alternative E (refer to Exhibit E2), the company would be able to pay both debts unless actual sales on the average drop 13.95% from the forecasted sales.

  1. Developing the World's Largest Commercial Jet.

    Boeing in this case would thus be adopting the "wait-and-see" approach as discussed earlier in their responses as they remain skeptical of A3XX's profit potential. However, we are assuming the passiveness of Boeing coupled with the confidence of aircraft buyers in the industry actually brought about an unexpected increase in the operation margins.

  2. Describe a Production Possibility Curve, and its importance. Consider points on the PPC and ...

    Around the mid 80s, beer used to be produced by nearly 450 companies in the U.S.A. The 450 companies consisted of many young and small companies, some medium-size and a few large companies. All the companies expanded the scales of operation and builds larger plants.

  • Over 160,000 pieces
    of student written work
  • Annotated by
    experienced teachers
  • Ideas and feedback to
    improve your own work